Lan Pham
Principal Scientist II Abbvie
Lan V. Pham is a Principal Scientist II in Oncology Discovery Research at AbbVie, where he focuses on identifying and advancing novel targeted therapies for cancer. His research includes the development of next generation ADC payloads, highlighted by his recent AACR work on first in class pan PI3K/mTOR dual inhibitors. This work demonstrated highly potent, selective payloads designed to overcome resistance and tolerability challenges associated with traditional small molecule inhibitors, with ADC delivery enabling improved efficacy, durable pathway inhibition, and strong bystander effects in tumor models.
Prior to AbbVie, Lan held academic roles at MD Anderson Cancer Center and brings deep expertise in cancer biology and translational oncology.
Seminars
- Breaking down rationale for pursuing PI3K inhibitor as a first-in-class payload, tackling challenges with anti-tumor potency and regression
- Spotlighting novel PI3K payload chemical structure with mTOR dual inhibition mechanism to deliver more potent and durable cytotoxic response
- Highlighting PI3K mTOR payload preclinical activity to date including in vitro mechanism of targeting pathway, efficacy in prioritised antigens and hyperglycaemia and skin toxicity safety characterization
